NCT01101464View on ClinicalTrials.gov

A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

December 31, 2002

Study Completion Date

December 31, 2002

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Asenapine 3x5mg followed by 1x15mg

Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days

DRUG

Asenapine 1x15mg followed by 3x5mg

One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT01101464 - A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937) | Biotech Hunter | Biotech Hunter